INHIBRX

Summary

Inhibrx is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics in oncology and orphan diseases.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 1.34 B

Avg. Deal Size£ 1.34 B

Market Context

Senior Management